232 related articles for article (PubMed ID: 29250436)
1. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice.
Nachbagauer R; Kinzler D; Choi A; Hirsh A; Beaulieu E; Lecrenier N; Innis BL; Palese P; Mallett CP; Krammer F
NPJ Vaccines; 2016; 1():16015-. PubMed ID: 29250436
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.
Bernstein DI; Guptill J; Naficy A; Nachbagauer R; Berlanda-Scorza F; Feser J; Wilson PC; Solórzano A; Van der Wielen M; Walter EB; Albrecht RA; Buschle KN; Chen YQ; Claeys C; Dickey M; Dugan HL; Ermler ME; Freeman D; Gao M; Gast C; Guthmiller JJ; Hai R; Henry C; Lan LY; McNeal M; Palm AE; Shaw DG; Stamper CT; Sun W; Sutton V; Tepora ME; Wahid R; Wenzel H; Wohlbold TJ; Innis BL; García-Sastre A; Palese P; Krammer F
Lancet Infect Dis; 2020 Jan; 20(1):80-91. PubMed ID: 31630990
[TBL] [Abstract][Full Text] [Related]
3. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Folschweiller N; Vanden Abeele C; Chu L; Van Damme P; García-Sastre A; Krammer F; Nachbagauer R; Palese P; Solórzano A; Bi D; David MP; Friel D; Innis BL; Koch J; Mallett CP; Rouxel RN; Salaun B; Vantomme V; Verheust C; Struyf F
Lancet Infect Dis; 2022 Jul; 22(7):1062-1075. PubMed ID: 35461522
[TBL] [Abstract][Full Text] [Related]
4. A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.
Bliss CM; Nachbagauer R; Mariottini C; Cuevas F; Feser J; Naficy A; Bernstein DI; Guptill J; Walter EB; Berlanda-Scorza F; Innis BL; García-Sastre A; Palese P; Krammer F; Coughlan L
EBioMedicine; 2024 Jun; 104():105153. PubMed ID: 38805853
[TBL] [Abstract][Full Text] [Related]
5. A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study.
Nachbagauer R; Krammer F; Albrecht RA
Vaccines (Basel); 2018 Jul; 6(3):. PubMed ID: 30044403
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.
Choi A; Bouzya B; Cortés Franco KD; Stadlbauer D; Rajabhathor A; Rouxel RN; Mainil R; Van der Wielen M; Palese P; García-Sastre A; Innis BL; Krammer F; Schotsaert M; Mallett CP; Nachbagauer R
Immunohorizons; 2019 Apr; 3(4):133-148. PubMed ID: 31032479
[TBL] [Abstract][Full Text] [Related]
7. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
[TBL] [Abstract][Full Text] [Related]
8. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
Front Immunol; 2019; 10():756. PubMed ID: 31105689
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
11. Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.
Nachbagauer R; Salaun B; Stadlbauer D; Behzadi MA; Friel D; Rajabhathor A; Choi A; Albrecht RA; Debois M; García-Sastre A; Rouxel RN; Sun W; Palese P; Mallett CP; Innis BL; Krammer F; Claeys C
NPJ Vaccines; 2019; 4():51. PubMed ID: 31839997
[TBL] [Abstract][Full Text] [Related]
12. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies.
Nachbagauer R; Liu WC; Choi A; Wohlbold TJ; Atlas T; Rajendran M; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Albrecht RA; Krammer F
NPJ Vaccines; 2017; 2():26. PubMed ID: 29263881
[TBL] [Abstract][Full Text] [Related]
13. Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.
Puente-Massaguer E; Vasilev K; Beyer A; Loganathan M; Francis B; Scherm MJ; Arunkumar GA; González-Domínguez I; Zhu X; Wilson IA; Coughlan L; Sun W; Palese P; Krammer F
Sci Adv; 2023 Sep; 9(37):eadi4753. PubMed ID: 37703367
[TBL] [Abstract][Full Text] [Related]
14. A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies.
Sunwoo SY; Schotsaert M; Morozov I; Davis AS; Li Y; Lee J; McDowell C; Meade P; Nachbagauer R; García-Sastre A; Ma W; Krammer F; Richt JA
Vaccines (Basel); 2018 Sep; 6(3):. PubMed ID: 30223475
[TBL] [Abstract][Full Text] [Related]
15. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
16. Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.
Kirchenbaum GA; Carter DM; Ross TM
J Virol; 2016 Jan; 90(2):1116-28. PubMed ID: 26559834
[TBL] [Abstract][Full Text] [Related]
17. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Nachbagauer R; Feser J; Naficy A; Bernstein DI; Guptill J; Walter EB; Berlanda-Scorza F; Stadlbauer D; Wilson PC; Aydillo T; Behzadi MA; Bhavsar D; Bliss C; Capuano C; Carreño JM; Chromikova V; Claeys C; Coughlan L; Freyn AW; Gast C; Javier A; Jiang K; Mariottini C; McMahon M; McNeal M; Solórzano A; Strohmeier S; Sun W; Van der Wielen M; Innis BL; García-Sastre A; Palese P; Krammer F
Nat Med; 2021 Jan; 27(1):106-114. PubMed ID: 33288923
[TBL] [Abstract][Full Text] [Related]
18. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
20. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
